αvβ6 integrin-A marker for the malignant potential of epithelial ovarian cancer
αvβ6 integrin-A marker for the malignant potential of epithelial ovarian cancer
复制标题
DOI：
10.1177/002215540205001010
复制
发表时间：
2002-10-01
影响因子：
3.2
通讯作者：
Baker, MS
中科院分区：
文献类型：
--
作者：
Ahmed, N;Riley, C;Baker, MS
导致非转移性或交界性卵巢癌进展为侵袭性I/III级卵巢癌的机制仍不清楚。上皮限制性整合素α（v）β（6）存在于恶性上皮中，但不存在于正常上皮中。我们研究了α（v）β（6）整合素在早期和晚期浸润性（I级和III级）和非浸润性（良性和交界性）浆液性、粘液性、类浆液性和透明细胞癌亚型卵巢肿瘤中的相对表达和分布，以评估其作为上皮性卵巢癌进展标志物的潜力。使用抗α（v）β（6）整合素的单克隆抗体（MAb）通过免疫组织化学（IHC）评价了66例标本，包括8例正常、13例良性、14例交界性、13例I级和18例III级肿瘤。正常卵巢表面上皮细胞α（v）β（6）整合素表达阴性。所有45例癌均为阳性，且染色强度与肿瘤分级显著相关。所有类型的III级癌均显示强染色强度。只有粘液性良性组织呈阳性，良性浆液性肿瘤中未观察到反应性。基于这些观察，我们假设α（v）β（6）整合素的表达与上皮性卵巢癌相关，并且该分子表达的逐渐增加可能是这种疾病进展的相关指标。
The mechanism(s) responsible for the progression of non-metastatic or borderline ovarian cancer to invasive Grade I/III ovarian cancer is still unknown. An epithelium-restricted integrin, alpha(v)beta(6), is present in malignant epithelia but not in normal epithelia. We studied the relative expression and distribution of alpha(v)beta(6) integrin in early and late-stage invasive (Grade I and Grade III) and non-invasive (benign and borderline) ovarian tumors of serous, mucinous, endometrioid, and clear-cell carcinoma subtypes, to assess its potential as a marker for epithelial ovarian cancer progression. Sixty-six specimens, including eight normal, 13 benign, 14 borderline, 13 Grade I, and 18 Grade III tumors were evaluated by immunohistochemistry (IHC) using a monoclonal antibody (MAb) against alpha(v)beta(6) integrin. Normal ovarian surface epithelium was negative for alpha(v)beta(6) integrin expression. All 45 carcinomas studied were positive, and the staining intensity significantly correlated with the grade of the tumor. The Grade III carcinomas of all types showed strong staining intensity. Only mucinous benign tissues were positive, and no reactivity was observed in benign serous neoplasms. On the basis of these observations, we hypothesize that the expression of alpha(v)beta(6) integrin is associated with epithelial ovarian cancer and that a gradual increase in the expression of the molecule may be a correlative index of the progression of this disease.